The nation of Zimbabwe has turned down a significant US health deal valued at $367m (£272m) over five years due to Washington's request for sensitive biological samples.
The decision came to light following a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesperson has since explained that the US was seeking biological samples for scientific study and profit while refused to share the benefits from future treatments.
"We must now begin the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for further dialogue to find a agreement suitable to all parties so the nation's critical HIV treatment initiative can proceed.
Broader Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a high court blocked a similar deal with the US following legal challenges were filed about the safety of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost openness and accountability.
According to reports, Sixteen nations in Africa have to date signed similar agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that might result from that shared data," his statement read.
"Put simply, our nation would supply the basic resources for scientific discovery without any assurance that the final treatments would be accessible to our people should a new disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were upending structures previously established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This system is designed to ensure that when a country provides its information, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage ongoing discussions with our American counterparts on how subsequent collaboration could be designed in a manner that respects the independence and interests of each country."
Health Experts Response
Medical experts expressed it acknowledged the official position, but urged that negotiations need to persist given that much of the country's Aids initiatives depended on external financing.
"In cases where technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group commented.
The halted deal emphasises the ongoing debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.